{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T02:17:41Z","timestamp":1793240261688,"version":"4.5.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"50","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1016\/j.vaccine.2013.10.019","type":"journal-article","created":{"date-parts":[[2013,10,24]],"date-time":"2013-10-24T05:15:45Z","timestamp":1382591745000},"page":"6022-6029","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["A relevant in vitro ELISA test in alternative to the in vivo NIH test for human rabies vaccine batch release"],"prefix":"10.1016","volume":"31","author":[{"given":"Richard","family":"Gibert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique","family":"Alberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Poirier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Jallet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"No\u00ebl","family":"Tordo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Morgeaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2013.10.019_bib0005","unstructured":"EC Administrative Procedure for Official Control Authority Batch Release: Control authority batch release of vaccines and blood products. Council of Europe. PA\/PH\/OMCL (12) 62 DEF."},{"key":"10.1016\/j.vaccine.2013.10.019_bib0010","unstructured":"WHO, Technical Report Series 941: Recommendations for inactivated rabies vaccine for human use produced in cell substrates and embryonated eggs; Geneva, 2007. p. 83."},{"key":"10.1016\/j.vaccine.2013.10.019_bib0015","unstructured":"European Pharmacopoeia. Rabies vaccine for human use prepared in cell cultures; 04\/2008. p. 822."},{"key":"10.1016\/j.vaccine.2013.10.019_bib0020","series-title":"Laboratory Techniques in Rabies","first-page":"279","article-title":"The NIH test for potency","author":"Seligmann","year":"1973"},{"key":"10.1016\/j.vaccine.2013.10.019_bib0025","first-page":"324","article-title":"Some observations related to the validity of potency tests for rabies vaccine","volume":"21","author":"Turner","year":"1974","journal-title":"Symp. Series Immunobiol. Standard."},{"key":"10.1016\/j.vaccine.2013.10.019_bib0030","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/0264-410X(88)90185-5","article-title":"NIH test, a problematic method for testing potency of inactivated rabies vaccine","volume":"6","author":"Barth","year":"1988","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.10.019_bib0035","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/0264-410X(91)90188-C","article-title":"The protective role of humoral neutralizing antibody antibody in the NIH potency test for rabies vaccines","volume":"9","author":"Wunderli","year":"1991","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.10.019_bib0040","first-page":"300","article-title":"Rabies vaccine potency testing: a comparison between the antibody-binding test and the NIH test","volume":"21","author":"Fitzgerald","year":"1974","journal-title":"Symp Series Immunobiol. Standard."},{"key":"10.1016\/j.vaccine.2013.10.019_bib0045","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0092-1157(81)80068-6","article-title":"The antibody-binding test, a useful method for quantitative determination of inactivated rabies virus antigen","volume":"9","author":"Barth","year":"1981","journal-title":"J. Biol. Standard."},{"key":"10.1016\/j.vaccine.2013.10.019_bib0050","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1099\/0022-1317-59-1-197","article-title":"A single-radial-immunodiffusion technique for the assay of rabies glycoprotein antigen: application for the potency tests of vaccines against rabies","volume":"59","author":"Ferguson","year":"1982","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.vaccine.2013.10.019_bib0055","first-page":"207","article-title":"Use of an enzyme immunoassay with protein A for rabies antigen and antibody determination","volume":"46","author":"Atanasiu","year":"1980","journal-title":"Develop. Biol. Standard."},{"key":"10.1016\/j.vaccine.2013.10.019_bib0060","first-page":"267","article-title":"Quantitative determination of rabies antigen by ELISA","volume":"50","author":"van der Marel","year":"1981","journal-title":"Develop. Biol. Standard."},{"key":"10.1016\/j.vaccine.2013.10.019_bib0065","first-page":"191","article-title":"The use of various immunochemical, biochemical and biological methods for the analysis of rabies virus production in tissue cultures","volume":"55","author":"Adamovicz","year":"1984","journal-title":"Develop. Biol. Standard."},{"key":"10.1016\/j.vaccine.2013.10.019_bib0070","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0092-1157(85)80042-1","article-title":"Use of monoclonal antibody for quantification nof rabies vaccine glycoprotein by enzyme immunoassay","volume":"13","author":"Lafon","year":"1985","journal-title":"J. Biol. Standard."},{"key":"10.1016\/j.vaccine.2013.10.019_bib0075","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0092-1157(89)80001-0","article-title":"Standardization of an enzyme immunoassay for the in vitro potency assay of inactivated tissue culture rabies vaccines: determination of the rabies virus glycoprotein with polyclonal antisera","volume":"17","author":"Thraenhart","year":"1989","journal-title":"J. Biol. Standard."},{"key":"10.1016\/j.vaccine.2013.10.019_bib0080","unstructured":"Official Authority Batch release of Rabies vaccines Guideline. Council of Europe. PA\/PH\/OMCL (11) 173 DEF."},{"key":"10.1016\/j.vaccine.2013.10.019_bib0085","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0092-1157(87)90018-7","article-title":"The effect of strain differences on the assay of rabies virus glycoprotein by single radial immunodiffusion","volume":"15","author":"Ferguson","year":"1987","journal-title":"J. Biol. Standard"},{"key":"10.1016\/j.vaccine.2013.10.019_bib0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0092-1157(87)90011-4","article-title":"Evaluation of the single readial-immunodiffusuion assay for measuring the glycoprotein content of rabies vaccines","volume":"15","author":"Mayner","year":"1987","journal-title":"J. Biol. Standard"},{"key":"10.1016\/j.vaccine.2013.10.019_bib0095","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0092-1157(84)80008-6","article-title":"A collaborative study on the use of single radial immunodiffusion for the assay of rabies virus glycoprotein","volume":"12","author":"Ferguson","year":"1984","journal-title":"Develop. Biol. Standard."},{"key":"10.1016\/j.vaccine.2013.10.019_bib0100","doi-asserted-by":"crossref","first-page":"269","DOI":"10.4049\/jimmunol.110.1.269","article-title":"Antigenic properties of rabies virus components","volume":"110","author":"Wiktor","year":"1973","journal-title":"J. Immunol."},{"key":"10.1016\/j.vaccine.2013.10.019_bib0105","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1006\/biol.1996.0012","article-title":"Use of ELISA for in vitro potency test of rabies vaccines for animal use","volume":"24","author":"Gamoh","year":"1996","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2013.10.019_bib0110","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/0042-6822(83)90349-5","article-title":"Chemical and immunological analysis of the rabies soluble glycoprotein","volume":"124","author":"Dietzschold","year":"1983","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2013.10.019_bib0115","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/1045-1056(90)90037-Z","article-title":"In vitro rabies vaccine potency appraisal by ELISA: advantages of the immunocapture method with a neutralizing anti-glycoprotein monoclonal antibody","volume":"18","author":"Perrin","year":"1990","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2013.10.019_bib0120","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0166-0934(95)01999-5","article-title":"Rabies vaccine potency control: comparison of ELISA systems for antigenicity testing","volume":"58","author":"Rooijakkers","year":"1996","journal-title":"J. Virol. Methods"},{"key":"10.1016\/j.vaccine.2013.10.019_bib0125","unstructured":"Rooijakkers EJ, Uittenbogaard JP, Groen J, van Herwijnen J, Osterhaus AD. Development and evaluation of alternative testing methods for the in vivo NIH potency test used for the quality control of inactivated rabies vaccines. In: Brown F, Cussler K, Hendriksen C editors. Replacement, reduction and refinement of animal experiments in the development and control of biological products. Dev. Biol. Stand; 1996; 137\u201345."},{"key":"10.1016\/j.vaccine.2013.10.019_bib0130","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1128\/JVI.73.1.225-233.1999","article-title":"Chimeric lyssavirus glycoproteins with increased immunological potential","volume":"73","author":"Jallet","year":"1999","journal-title":"J. Virol."},{"key":"10.1016\/j.vaccine.2013.10.019_bib0135","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S1045-1056(02)00070-2","article-title":"Inactivated rabies vaccine control and release: use of an ELISA method","volume":"31","author":"Fournier-Caruana","year":"2003","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2013.10.019_bib0140","unstructured":"Milstien J, Grachev V, Padilla A, Griffiths E. WHO activities towards the three Rs in the development and control of biological products. In: Brown F, Cussler K, Hendriksen C editors. Replacement, reduction and refinement of animal experiments in the development and control of biological products. Dev. Biol. Stand; 1996. 31\u201339."},{"key":"10.1016\/j.vaccine.2013.10.019_bib0145","first-page":"21","article-title":"Contributions of the European OMCL Network and Biological Standardisation Programme to animal Welfare","volume":"23","author":"Behr-Gross","year":"2006","journal-title":"Altex"},{"key":"10.1016\/j.vaccine.2013.10.019_bib0150","unstructured":"Directive 2010\/63\/EU of the European Parliament and the Council of 22 September 2010 on the protection of animals used for scientific purposes. Official Journal of European Union. 2010; L276; 33-79."},{"key":"10.1016\/j.vaccine.2013.10.019_bib0155","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S1045-1056(05)80062-4","article-title":"Report of a collaborative study to assess the determination of glycoprotein antigen content of rabies vaccines for human use","volume":"20","author":"Ferguson","year":"1992","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2013.10.019_bib0160","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.biologicals.2012.07.005","article-title":"Report on the international workshop on alternative methods for human and veterinary rabies vaccine testing: state of the science and planning the way forward","volume":"40","author":"Stokes","year":"2012","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2013.10.019_bib0165","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1099\/vir.0.81063-0","article-title":"Stable trimerization of recombinant rabies virus glycoprotein ectodomain is required for interaction with the p75NTR receptor","volume":"86","author":"Sisso\u00ebff","year":"2005","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.vaccine.2013.10.019_bib0170","series-title":"Monoclonal Antibodies Symposium. Dev. Biol. Standard., 57","first-page":"213","article-title":"production of monoclonal antibodies against Pasteur virus (PV strain): problem and results","author":"Libeau","year":"1984"},{"key":"10.1016\/j.vaccine.2013.10.019_bib0175","unstructured":"European Pharmacopoeia. Statistical analysis of results of biological assays and tests; 01\/2008. p. 551."},{"key":"10.1016\/j.vaccine.2013.10.019_bib0180","first-page":"183","article-title":"Use of the antibody assay in immunized mice for the determination of rabies vaccine potency","volume":"40","author":"Fitzgerald","year":"1978","journal-title":"Dev. Biol. Standard."},{"key":"10.1016\/j.vaccine.2013.10.019_bib0185","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.biologicals.2009.01.001","article-title":"The rapid fluorescent focus inhibition test is a suitable method batch potency testing of inactivated rabies vaccines","volume":"37","author":"Kr\u00e4mer","year":"2009","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2013.10.019_bib0190","unstructured":"European Pharmacopoeia. Rabies vaccine (inactivated) for veterinary use; 04\/2013. p. 5385."},{"key":"10.1016\/j.vaccine.2013.10.019_bib0195","unstructured":"European Pharmacopoeia. In vivo Assay of poliomyelitis vaccine (inactivated); 01\/2008. p. 225."},{"key":"10.1016\/j.vaccine.2013.10.019_bib0200","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1073\/pnas.80.1.70","article-title":"Characterization of an antigenic determinant of the glycoprotein that correlates with pathogenicity of rabies virus","volume":"80","author":"Dietzschold","year":"1983","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.vaccine.2013.10.019_bib0205","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1128\/JVI.53.3.926-934.1985","article-title":"Rabies virulence: effect on pathogenicity and sequence characterization of rabies virus mutations affecting antigenic site III of the glycoprotein","volume":"53","author":"Seif","year":"1985","journal-title":"J. Virol."},{"key":"10.1016\/j.vaccine.2013.10.019_bib0210","doi-asserted-by":"crossref","first-page":"7250","DOI":"10.1093\/emboj\/17.24.7250","article-title":"Low-affinity nerve-growth factor receptor (P75NTR) can serve as a receptor for rabies virus","volume":"17","author":"Tuffereau","year":"1998","journal-title":"EMBO J"},{"key":"10.1016\/j.vaccine.2013.10.019_bib0215","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1002\/eji.200526134","article-title":"The human antibody repertoire specific for rabies virus glycoprotein as selected from immune libraries","volume":"35","author":"Kramer","year":"2005","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.vaccine.2013.10.019_bib0220","doi-asserted-by":"crossref","first-page":"9062","DOI":"10.1128\/JVI.79.14.9062-9068.2005","article-title":"Novel Human Monoclonal Antibody Combination Effectively neutralizing natural rabies virus variants and individual in vitro escape mutants","volume":"79","author":"Bakker","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.vaccine.2013.10.019_bib0225","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1016\/j.vaccine.2006.12.031","article-title":"Identification and characterization of a human monoclonal antibody that potently neutralizes a broad panel of rabies virus isolates","volume":"25","author":"Sloan","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.10.019_bib0230","doi-asserted-by":"crossref","first-page":"4648","DOI":"10.1016\/j.vaccine.2009.05.055","article-title":"Peptide mimotopes of rabies virus glycoprotein with immunogenic activity","volume":"27","author":"Houimel","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.10.019_bib0235","first-page":"1","article-title":"Development of a mouse monoclonal antibody cocktail for post-exposure rabies prophylaxis in humans","volume":"3","author":"M\u00fcller","year":"2009","journal-title":"PLoS"},{"key":"10.1016\/j.vaccine.2013.10.019_bib0240","first-page":"25","article-title":"A purified human diploid cell rabies vaccine","volume":"40","author":"Majer","year":"1978","journal-title":"Dev. Biol. Stand."},{"key":"10.1016\/j.vaccine.2013.10.019_bib0245","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/0006-3002(61)90419-X","article-title":"Polarographic experiments on the interaction of B-propiolactone with albumin thiol and disulphide groups","volume":"52","author":"Searle","year":"1961","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.vaccine.2013.10.019_bib0250","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/JVI.62.1.1-7.1988","article-title":"Antigenic site II of the rabies virus glycoprotein: structure and role in viral virulence","volume":"62","author":"Prehaud","year":"1988","journal-title":"J. Virol."},{"key":"10.1016\/j.vaccine.2013.10.019_bib0255","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1099\/0022-1317-64-4-843","article-title":"Antigenic sites on the CVS rabies virus glycoprotein: analysis with monoclonal antibodies","volume":"64","author":"Lafon","year":"1983","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.vaccine.2013.10.019_bib0260","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/j.1348-0421.2003.tb03412.x","article-title":"Mapping of the low pH-sensitive conformational epitope of rabies virus glycoprotein recognized by a monoclonal antibody # 1-30-44","volume":"47","author":"Kankanamge","year":"2003","journal-title":"Microbiol. Immunol."},{"key":"10.1016\/j.vaccine.2013.10.019_bib0265","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.biologicals.2005.07.004","article-title":"A simple immuno-capture ELISA to estimate rabies viral glycoprotein antigen in vaccine manufacture","volume":"34","author":"Nagarajan","year":"2006","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2013.10.019_bib0270","first-page":"1261","article-title":"Recombinant diabody-based immunocapture enzyme-linked immunosorbent assay for quantification of rabies virus glycoprotein","volume":"17","author":"Sridevi","year":"2012","journal-title":"Clin Vac Immunol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X13013844?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X13013844?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T15:27:18Z","timestamp":1688570838000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X13013844"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":54,"journal-issue":{"issue":"50","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S0264410X13013844"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2013.10.019","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A relevant in vitro ELISA test in alternative to the in vivo NIH test for human rabies vaccine batch release","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2013.10.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}